Raymond James Reiterates Strong Buy Rating on Palvella Therapeutics (PVLA)

February 23, 2026 6:57 AM EST Send to a Friend
Raymond James analyst Ryan Deschner reiterated a Strong Buy rating and $193.00 price target on Palvella Therapeutics (NASDAQ: PVLA).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login